166 related articles for article (PubMed ID: 36883638)
1. Defining estimands in clinical trials: A unified procedure.
Han S; Zhou XH
Stat Med; 2023 May; 42(12):1869-1887. PubMed ID: 36883638
[TBL] [Abstract][Full Text] [Related]
2. Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice.
Ratitch B; Bell J; Mallinckrodt C; Bartlett JW; Goel N; Molenberghs G; O'Kelly M; Singh P; Lipkovich I
Ther Innov Regul Sci; 2020 Mar; 54(2):324-341. PubMed ID: 32072573
[TBL] [Abstract][Full Text] [Related]
3. Aligning Estimators With Estimands in Clinical Trials: Putting the ICH E9(R1) Guidelines Into Practice.
Mallinckrodt CH; Bell J; Liu G; Ratitch B; O'Kelly M; Lipkovich I; Singh P; Xu L; Molenberghs G
Ther Innov Regul Sci; 2020 Mar; 54(2):353-364. PubMed ID: 32072593
[TBL] [Abstract][Full Text] [Related]
4. Estimation of treatment effects in short-term depression studies. An evaluation based on the ICH E9(R1) estimands framework.
Mitroiu M; Teerenstra S; Oude Rengerink K; Pétavy F; Roes KCB
Pharm Stat; 2022 Sep; 21(5):1037-1057. PubMed ID: 35678545
[TBL] [Abstract][Full Text] [Related]
5. Single-world intervention graphs for defining, identifying, and communicating estimands in clinical trials.
Ocampo A; Bather JR
Stat Med; 2023 Sep; 42(21):3892-3902. PubMed ID: 37340887
[TBL] [Abstract][Full Text] [Related]
6. A narrative review of estimands in drug development and regulatory evaluation: old wine in new barrels?
Mitroiu M; Oude Rengerink K; Teerenstra S; Pétavy F; Roes KCB
Trials; 2020 Jul; 21(1):671. PubMed ID: 32703247
[TBL] [Abstract][Full Text] [Related]
7. Implementation of tripartite estimands using adherence causal estimators under the causal inference framework.
Qu Y; Luo J; Ruberg SJ
Pharm Stat; 2021 Jan; 20(1):55-67. PubMed ID: 33442928
[TBL] [Abstract][Full Text] [Related]
8. Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) Guidelines.
Ratitch B; Goel N; Mallinckrodt C; Bell J; Bartlett JW; Molenberghs G; Singh P; Lipkovich I; O'Kelly M
Ther Innov Regul Sci; 2020 Mar; 54(2):370-384. PubMed ID: 32072586
[TBL] [Abstract][Full Text] [Related]
9. Incorporating estimands into clinical trial statistical analysis plans.
Kang M; Kendall MA; Ribaudo H; Tierney C; Zheng L; Smeaton L; Lindsey JC
Clin Trials; 2022 Jun; 19(3):285-291. PubMed ID: 35257600
[TBL] [Abstract][Full Text] [Related]
10. Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic.
Qu Y; Lipkovich I
Ther Innov Regul Sci; 2021 Sep; 55(5):984-988. PubMed ID: 33983621
[TBL] [Abstract][Full Text] [Related]
11. Estimands: discussion points from the PSI estimands and sensitivity expert group.
Phillips A; Abellan-Andres J; Soren A; Bretz F; Fletcher C; France L; Garrett A; Harris R; Kjaer M; Keene O; Morgan D; O'Kelly M; Roger J
Pharm Stat; 2017 Jan; 16(1):6-11. PubMed ID: 26997517
[TBL] [Abstract][Full Text] [Related]
12. Defining Clinical Trial Estimands: A Practical Guide for Study Teams with Examples Based on a Psychiatric Disorder.
Polverejan E; O'Kelly M; Hefting N; Norton JD; Lim P; Walton MK
Ther Innov Regul Sci; 2023 Sep; 57(5):911-939. PubMed ID: 37244885
[TBL] [Abstract][Full Text] [Related]
13. Hypothetical Estimands in Clinical Trials: A Unification of Causal Inference and Missing Data Methods.
Olarte Parra C; Daniel RM; Bartlett JW
Stat Biopharm Res; 2023; 15(2):421-432. PubMed ID: 37260584
[TBL] [Abstract][Full Text] [Related]
14. Estimands in practice: Bridging the gap between study objectives and statistical analysis.
Phillips A; Clark T
Pharm Stat; 2021 Jan; 20(1):68-76. PubMed ID: 32893473
[TBL] [Abstract][Full Text] [Related]
15. Tell me what you want, what you really really want: Estimands in observational pharmacoepidemiologic comparative effectiveness and safety studies.
Luijken K; van Eekelen R; Gardarsdottir H; Groenwold RHH; van Geloven N
Pharmacoepidemiol Drug Saf; 2023 Aug; 32(8):863-872. PubMed ID: 36946319
[TBL] [Abstract][Full Text] [Related]
16. Estimand framework: Delineating what to be estimated with clinical questions of interest in clinical trials.
Jin M; Liu G
Contemp Clin Trials; 2020 Sep; 96():106093. PubMed ID: 32777382
[TBL] [Abstract][Full Text] [Related]
17. Is Intention to Treat Still the Gold Standard or Should Health Technology Assessment Agencies Embrace a Broader Estimands Framework?: Insights and Perspectives From the National Institute for Health and Care Excellence and Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9 (R1) Addendum.
Morga A; Latimer NR; Scott M; Hawkins N; Schlichting M; Wang J
Value Health; 2023 Feb; 26(2):234-242. PubMed ID: 36150999
[TBL] [Abstract][Full Text] [Related]
18. Estimands for atopic dermatitis clinical trials: Expert opinion on the importance of intercurrent events.
Bissonnette R; Eichenfield LF; Simpson E; Thaçi D; Kabashima K; Thyssen JP; Guttman-Yassky E; Nunes FP; Gamalo M; Ahmad F; Kuligowski M; Sun K; Pipper C; Christensen AW; D'Angelo P; Milutinovic M; Guettner A; Silverberg JI
J Eur Acad Dermatol Venereol; 2023 May; 37(5):976-983. PubMed ID: 36652273
[TBL] [Abstract][Full Text] [Related]
19. Marking 2-Years of New Thinking in Clinical Trials: The Estimand Journey.
Fletcher C; Hefting N; Wright M; Bell J; Anzures-Cabrera J; Wright D; Lynggaard H; Schueler A
Ther Innov Regul Sci; 2022 Jul; 56(4):637-650. PubMed ID: 35462609
[TBL] [Abstract][Full Text] [Related]
20. Handling intercurrent events and missing data in non-inferiority trials using the estimand framework: A tuberculosis case study.
Rehal S; Cro S; Phillips PP; Fielding K; Carpenter JR
Clin Trials; 2023 Oct; 20(5):497-506. PubMed ID: 37277978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
